Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 204

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action

Open access
Willsmore, Zena N., Coumbe, Ben G. T., Crescioli, Silvia, Reci, Sara, Gupta, Ayushi, Harris, Robert J., Chenoweth, Alicia, Chauhan, Jitesh, Bax, Heather J., McCraw, Alexa, Cheung, Anthony, Osborn, Gabriel, Hoffmann, Ricarda M., Nakamura, Mano, Laddach, Roman, Geh, Jenny L. C., MacKenzie‐Ross, Alastair, Healy, Ciaran, Tsoka, Sophia, Spicer, James F., Josephs, Debra H., Papa, Sophie, Lacy, Katie E., Karagiannis, Sophia N. · 2021 · European Journal of Immunology

Abstract

Cytotoxic T‐lymphocyte associated protein‐4 (CTLA‐4) and the Programmed Death Receptor 1 (PD‐1) are immune checkpoint molecules that are well‐established targets of antibody immunotherapies for the management of malignant melanoma. The monoclonal antibodies, Ipilimumab, Pembrolizumab, and Nivolumab, designed to interfere with T cell inhibitory signals to activate immune responses against tumors, were originally approved as monotherapy. Treatment with a combination of immune checkpoint inhibitors may improve outcomes compared to monotherapy in certain patient groups and these clinical benefits may be derived from unique immune mechanisms of action. However, treatment with checkpoint inhibitor combinations also present significant clinical challenges and increased rates of immune‐related adverse events. In this review, we discuss the potential mechanisms attributed to single and combined checkpoint inhibitor immunotherapies and clinical experience with their use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/eji.202048747

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 204

Metadata

Authors
Willsmore, Z. N., Coumbe, B. G. T., Crescioli, S., Reci, S., Gupta, A., Harris, R. J., Chenoweth, A., Chauhan, J., Bax, H. J., McCraw, A., Cheung, A., Osborn, G., Hoffmann, R. M., Nakamura, M., Laddach, R., Geh, J. L. C., MacKenzie‐Ross, A., Healy, C., Tsoka, S., Spicer, J. F., Josephs, D. H., Papa, S., Lacy, K. E., & Karagiannis, S. N.
Venue
European Journal of Immunology
Publisher
Wiley
Published
2021-02-23
Volume
51
Issue
3
Pages
544-556
ISSN
  • 0014-2980 (ISSN-L)
  • 1521-4141
OpenAlex
W3124047768
Cited by
204
References
39
FWCI
10.19
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. https://app.cochat.ai/papers/10.1002/eji.202048747
The paper
Willsmore, Z. N., Coumbe, B. G. T., Crescioli, S., Reci, S., Gupta, A., Harris, R. J., Chenoweth, A., Chauhan, J., Bax, H. J., McCraw, A., Cheung, A., Osborn, G., Hoffmann, R. M., Nakamura, M., Laddach, R., Geh, J. L. C., MacKenzie‐Ross, A., Healy, C., Tsoka, S., . . . Karagiannis, S. N. (2021). Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. European Journal of Immunology. https://doi.org/10.1002/eji.202048747

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.